SCHEMBL6486556

SCHEMBL6486556

Nc1ccc(-c2ccc(C(=O)NC3CC4CC3CN4)o2)cc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 8/20 0.42
POLB P06746 1/20 0.42
NPC1 O15118 4/20 0.42
RAB9A P51151 4/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
KDM4E B2RXH2 8/20 0.41
MAPT P10636 3/20 0.41
KMT2A Q03164 2/20 0.41
NPSR1 Q6W5P4 2/20 0.41
MEN1 O00255 1/20 0.41
SMN1; SMN2 Q16637 4/20 0.39
HPGD P15428 4/20 0.39
GAA P10253 1/20 0.39
HSD17B10 Q99714 1/20 0.39
LMNA P02545 5/20 0.38
GPR55 Q9Y2T6 1/20 0.38
PTPN1 P18031 1/20 0.38
PTPN11 Q06124 1/20 0.38
MAPK1 P28482 1/20 0.37
AKT1 P31749 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6485912 0.90 ALDH1A1 (0.43) ALDH1A1POLBNPC1RAB9AL3MBTL1
SCHEMBL6489856 0.90 ERCC5 (0.45) ALDH1A1POLBNPC1RAB9AL3MBTL1
SCHEMBL6502351 0.89 ALDH1A1 (0.52) ALDH1A1POLBNPC1RAB9AL3MBTL1
SCHEMBL6489862 0.89 NPC1 (0.56) ALDH1A1POLBNPC1RAB9AL3MBTL1
SCHEMBL6489595 0.89 MMP13 (0.43) ALDH1A1POLBNPC1RAB9AL3MBTL1
SCHEMBL6499804 0.88 ALDH1A1 (0.44) ALDH1A1POLBNPC1RAB9AL3MBTL1
SCHEMBL6499881 0.87 MAPKAPK2 (0.45) ALDH1A1POLBNPC1RAB9AL3MBTL1
SCHEMBL6490649 0.85 MEN1 (0.49) ALDH1A1POLBNPC1RAB9AL3MBTL1
SCHEMBL6486675 0.83 SLC9A1 (0.44) ALDH1A1NPC1RAB9AKDM4EMAPT
SCHEMBL6499550 0.82 MAPKAPK2 (0.41) ALDH1A1POLBNPC1RAB9AL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6919359-B2 Azabicyclic-substituted-heteroaryl compounds for the treatment of disease PFIZER INC (US) 2005-07-19 US claimed
US-20030207913-A1 Azabicyclic-substituted-heteroaryl compounds for the treatment of disease PHARMACIA & UPJOHN COMPANY 2003-11-06 US claimed
US-6919359-B2 Azabicyclic-substituted-heteroaryl compounds for the treatment of disease PFIZER INC (US) 2005-07-19 US disclosed
US-20030207913-A1 Azabicyclic-substituted-heteroaryl compounds for the treatment of disease PHARMACIA & UPJOHN COMPANY 2003-11-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030207913-A1 Azabicyclic-substituted-heteroaryl compounds for the treatment of disease MALT1, WFS1, NR5A1 ALDH1A1 625/4885POLB 1370/4885NPC1 224/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.